STUDY QUESTION: Is transferring embryos that achieve blastulation on Day 7 effective and safe?
Introduction
Improvements of extended embryo culture techniques now allow embryos derived from IVF to develop for more than 3 days in vitro before being transferred back into the uterus. The advantages that have been reported of blastocyst transfer over cleavage embryo transfer include a better synchrony with the endometrium, and that the extend culture could serve as a possible selection process for embryos of superior viability and less genetic abnormality (Shoukir et al., 1998; Adler et al., 2014) . Indeed, higher clinical pregnancy and live birth rates have been observed after blastocyst transfer compared with cleavage embryo transfer, although the quality of the data is limited (Glujovsky et al., 2016) . In addition, the risk of multiple pregnancy as well as ectopic pregnancy can also be reduced by the application of single blastocyst transfer strategy (Du et al., 2017) . These advantages have led to a shift from cleavage embryo transfer to blastocyst transfer in IVF practice (Glujovsky et al., 2016) .
Among embryos that successfully developed into blastocysts, only about 67% can achieve blastulation by Day 6, while nearly 29% are doing this on Day 7 (Shoukir et al., 1998) . Thus, Day 7 blastocysts are alternatives for Day 5 or 6 blastocysts. However, published data about the fertility outcomes of Day 7 blastocysts are scarce and controversial (Table I) . Early studies reported that the pregnancy rate of Day-7 blastocyst transfer was <10% (Shoukir et al., 1998; Utsunomiya et al., 2004) , which has led to a common practice of discarding embryos that do not achieve blastulation by Day 6 (Kovalevsky et al., 2013) . However, more recent studies showed the pregnancy rate after Day-7 blastocyst transfer was of clinical importance, and could even reach more than 50%, similar to Day-5 or Day-6 blastocyst transfers (Hiraoka et al., 2008; Kovalevsky et al., 2013) . Most of these studies had a limited sample size or were even case reports. Moreover, there are few data available on the neonatal outcomes of infants derived from Day 7 blastocysts in the literature, which makes the clinical implementation of Day-7 blastocyst transfer uncertain.
The aim of this study was to assess the fertility and neonatal outcomes of Day 7 blastocysts as compared to Day 5 and Day 6 blastocysts.
Materials and Methods

Study population and design
This was a retrospective cohort study based on data collected from the Department of Assisted Reproduction of Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine. We studied fertility and neonatal outcomes of women undergoing autologous Day-5, Day-6 and Day-7 vitrified embryo transfers after IVF/ICSI from January 2006 to May 2015. After excluding women that had transferred multiple blastocysts vitrified on different days, the remaining women were subclassed into groups of those who had pure Day-5, Day-6 and Day-7 vitrified embryo transfers, respectively ( Fig. 1 ). Repeated cycles from the same women were not used.
Ethical approval
This study was approved by the Institutional Review Board of the hospital.
Analysis
The study included two parts (Fig. 1) . First, we compared the fertility outcomes of Day-5, Day-6 and Day-7 vitrified embryo transfers in propensity score matched cohorts (Day 5 vs Day 6, Day 5 vs Day 7 and Day 6 vs Day 7) (Whittaker et al., 2016) . Propensity scores were calculated using logistic regression based on patient and frozen-thawed embryo transfer (FET) characteristics including female age, female BMI, duration of infertility, gravidity, parity, number of previous full term births, presence of tubal factor infertility (as diagnosed by tubal obstruction, tubal adhesion or a previous salpingitis), polycystic ovarian syndrome (PCOS), endometriosis and male factor infertility (defined as oligoasthenoteratozoospermia or azoospermia: sperm concentration <15 × 10 6 /mL, vitality <40%, motility <32%, normal morphology <4%) (Organization, 2010) , type of endometrial preparation (natural cycles, hormone therapy cycles and stimulated cycles), endometrial thickness on embryo transfer (ET) day, number of embryos transferred, and year of treatment (2006-2009, 2010-2011, 2012-2013, 2014-2015) . Matches without replacement were performed using propensity scores through the nearest neighbor random matching algorithm. The matched ratios for Day 5 group vs Day 6 group, Day 5 group vs Day 7 group, and Day 6 group vs Day 7 group were 1:1, 2:1 and 3:1, respectively.
In the second part of the study, neonatal outcomes were compared among the babies born from the Day-5, Day-6 and Day-7 vitrified embryo transfers. To do so, we excluded children born to mothers with reported maternal diseases during pregnancy, such as hypertension (Van Zutphen et al., 2014) , gestational diabetes mellitus (Keshavarz et al., 2005) and thyroid disorders (Devos et al., 1999; Khoury et al., 1989) to eliminate the possible effect of these factors on birth defects.
Treatment
IVF/ICSI procedures have been described in our previous studies (Kuang et al., 2014a (Kuang et al., , 2014b (Kuang et al., , 2015 Chen et al., 2015 criteria (Cummins et al., 1986) were used to grade Day 3 embryos from IVF/ICSI. Only embryos classified as top-quality (grade I and II) were used for vitrification. Embryos graded as quality III and IV were extendedly cultured and observed until they reached the blastocyst stage up to Day 7. For blastocysts, the Gardner and Schoolcraft grade system (Gardner and Lane, 2000) was applied. On Day 5 or 6, only embryos grade 3BC or higher were vitrified, while the blastocysts had to be at least 3CC to be qualified for vitrification on Day 7. Day 3 embryos were of higher priority for transfer over blastocysts. For women without Day 3 embryos, blastocysts with better grades were of higher priority for transfer, irrespective of the vitrification day.
Notably, during the study period, a main change had occurred in the laboratory. Before 2013, embryos were cultured in early cleavage medium (Irvine Scientific, USA) before Day 3, and in Multiblast Medium (Irvine Scientific, USA) thereafter, whereas since 2013, all embryos were cultured in Continuous Single Culture (Irvine Scientific, USA) throughout the entire development stage.
Endometrial preparation and FET were performed in natural cycles, hormone therapy cycles or stimulation cycles, as described previously (Du et al., 2017) . In short, in patients with regular menstrual cycles, FET was performed in a natural cycle. For patients with irregular menstrual cycles, letrozole and, if necessary, human menopausal gonadotropin were used to stimulate monofollicular growth. In patients with a history of thin endometrium during either natural cycles or stimulation cycles, hormonal therapy was applied. Specifically, from cycle Day 3 onwards, oral E 2 (ethinylestradiol; Shanghai Xinyi Pharma, China) 75 ug/day was administered. When the endometrial thickness was >8 mm, or E 2 had been administrated 42 days, four yellow Femoston tablets Figure 1 Flow chart of the study.
(Solvay Pharmaceuticals B.V., USA) (total of 8 mg oestradiol and 40 mg dydrogesterone) per day were started. The progestin (P) supplement was continued until 8 weeks of gestation if pregnancy was achieved.
Outcome assessment
Serum β-hCG level was measured 14 days after embryo transfer. In women with positive results in serum β-hCG test, transvaginal ultrasonography was routinely performed 35 days after embryo transfer.
The follow-up system in our center has been described previously . Briefly, the couples completed telephone interviews during each stage of pregnancy, up to 1 week after delivery. The interview questionnaire collected information about a wide range of pregnancy exposures, pregnancy complications, birth date and locality, gestational weeks, mode of delivery, birth weight, infant gender and neonatal diseases. For neonatal data, in case the parental questionnaire did not report abnormalities of the baby, this was considered sufficient. In cases the parental questionnaire mentioned an abnormality of the baby, the couples were further questioned about specific disease indicators, including diagnosis, time of diagnosis, treatment and outcome. For babies born in our university hospital, medical records of detailed physical examination and routine ultrasound examination of the brain, kidneys and heart were obtained, while for babies born elsewhere, written reports were obtained from the responsible pediatrician. When attempts to contact couples failed, information on the questionnaire was investigated through family planning service agencies. In summary, as for the main measures of the neonatal outcomes in the current study, birth weight was from questionnaire only, positive cases of birth defects and neonatal death were confirmed by medical records. Furthermore, in case live born infants had birth defects, pertinent information was reviewed by a specially designated nurse, to guarantee that children met the case definition of the Chinese Birth Defects Monitoring Program.
Fertility outcomes were defined based on the International Committee for Monitoring Assisted Reproductive Technology and the World Health Organization revised glossary of ART terminology 2009 (Zegers-Hochschild et al., 2009). Intrauterine implantation was defined as the attachment and subsequent penetration by the zona-free blastocyst in the endometrium that starts 5-7 days after fertilization. Intrauterine implantation rate was calculated as the number of intrauterine gestational sacs observed divided by the number of embryos transferred. Biochemical pregnancy was defined as a pregnancy diagnosed only by the detection of hCG in serum and that does not develop into a clinical pregnancy. Clinical pregnancy was defined as a pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy. It includes ectopic pregnancy. Miscarriage rate was calculated as the total number of induced and spontaneous miscarriages divided by the number of clinical pregnancies. Live birth rate was calculated as the number of deliveries that resulted in at least one live born baby, expressed per 100 embryo transfer cycles. Lost to follow-up was defined as the final pregnancy outcome of a confirmed clinical pregnancy could not be obtained after the expected date of delivery. Low birth weight was defined as birth weight <2500 g. Early neonatal death was defined as death of a live born baby within 7 days of birth. Congenital malformations were classified according to the International Classification of Diseases Q codes (Q00-Q99) as conditions registered in the International Statistical Classification of Diseases and Related Health Problems (Vukasinović et al., 1994) .
Statistical analyses
Statistical analysis was carried out by SPSS version 23.0 software (SPSS Inc., Chicago, USA). The normality of quantitative data was tested both by the Kolmogorov-Smirnova and Shapiro-Wilk tests. Since none of the quantitative variables studied demonstrated normal distribution by both tests, they are presented as medians (first quartile, third quartile), while qualitative data are presented as % (n/N). The nonparametric Mann-Whitney U test was applied to analyze the differences in the means of two independent nonnormal distribution samples, and comparisons of rates were performed by the chi-square test or Fisher's exact test as appropriate. Observed Power was computed with an α of 0.017 by G*Power (Faul et al., 2007) .
In the propensity score matching analysis, a P-value <0.017 was considered to indicate statistical significance (Bonferroni adjustment for multiple comparisons). For other comparisons, a P-value <0.05 was considered to indicate statistical significance.
In part I of the study, a binary logistic regression was performed to investigate the effect of potential risk factors on implantation failure using all the single blastocyst transfer cycles (n = 1260) derived from all the included transfers. Potential risk factors, including vitrification day of embryos transferred, embryo stage and embryo grade according to the Gardner and Schoolcraft grade system (Gardner and Lane, 2000) , plus the aforementioned factors used in propensity score calculation despite number of embryos transferred, were introduced into the regression equation by the backward conditional method.
In part II, we performed a binary logistic regression to investigate the effect of potential risk factors on congenital malformations using all the cycles from which the studied infants derived. Potential risk factors, including the aforementioned factors used in propensity score calculation plus multiple birth and vitrification day of embryos transferred, were introduced into the regression equation by the forward conditional method.
Unadjusted and adjusted odds ratios (ORs) and 95% CIs were calculated by the regression models. The −2 log likelihood was used to calculate the significance of the models, and the Nagelkerke's R 2 was used to evaluate and explain uncertainty.
Results
Fertility outcomes
A total of 2908 women were included, which were subclassed into 922, 1752 and 234 women with Day-5, Day-6 and Day-7 vitrified embryo transfer groups, respectively (Fig. 1) . The overall clinical pregnancy and live birth rates of Day-7 vitrified embryo transfers were 32.5 and 25.2%, respectively. The 2908 FET cycles from the included women were matched into 921 pairs of cycles in Day 5 vs Day 6 cohorts, 227 triplets of cycles in Day 5 vs Day 7 cohorts, and 227 tetrads of cycles in Day 6 vs Day 7 cohorts (Fig. 1) . The distributions of propensity scores and standard deviations before and after matching are shown in Fig. 2 . The distributions of propensity scores and standard differences indicated balance between the comparing cohorts. Characteristics of the matched Day-5, Day-6 and Day-7 vitrified embryo transfer groups are shown in Table II . The stages and grades of blastocysts in each group are shown in Fig. 3 . Both the proportion of higher stage blastocysts and the proportion of embryos with inferior grades were significantly higher in blastocysts of lower growth rates. Fertility outcomes are shown in Table III . Both Day-5 (49.9 vs 23.9%, 58.1 vs 31.7% and 46.5 vs 25.1%, all P < 0.001, respectively) and 53 .2 vs 33.0% and 41.4 vs 25.6%, all P<0.001, respectively) vitrified embryo transfers had significantly higher rates of intrauterine implantation, clinical pregnancy and live birth than Day-7 vitrified embryo transfers. Also, Day-5 vitrified embryo transfers had significantly higher rates of multiple gestation and multiple birth compared to both Day-6 (33.2 vs 21.6%, and 36.0 vs 22.4%, both P<0.001, respectively) and Day-7 (31.1 vs 13.9%, P = 0.004, and 33.6 vs 15.8%, P = 0.009, respectively) vitrified embryo transfers. Moreover, the rates of intrauterine implantation (50.4 vs 42.1%, P < 0.001) and clinical pregnancy (60.2 vs 54.4%, P = 0.013) were significantly higher in Day-5 vitrified embryo transfers than in Day-6 vitrified embryo transfers. Biochemical pregnancy, ectopic pregnancy and miscarriage rates as well as gestational age were not statistically significantly different between the matched cohorts.
Unadjusted and adjusted ORs and 95% CIs of the potential risk factors for implantation failure are shown in Table IV. In the adjusted analysis, women between 38 and 40 (OR: 0.61, 95% CI: 0.39-0.95) and ≥41 years (OR: 0.46, 95% CI: 0.25-0.83) had a significantly lower incidence of implantation than women <30 years. Blastocysts in stage 4 (OR: 1.95, 95% CI: 1.14-3.33) and 5 (OR: 2.40, 95% CI: 1.09-5.25) had significantly higher implantation potential compared with those in stage 3, whereas blastocysts of grades BB (OR: 0.47, 95% CI: 0.29-0.74), AC/BC/CB (OR: 0.38, 95% CI: 0.23-0.64), and CC (OR: 0.08, 95% CI: 0.02-0.30) had significantly lower implantation potential than those of grade AA. Especially, vitrification day of embryos transferred was an independent risk factor for implantation failure. Day 7 blastocysts were associated with a significantly higher risk of implantation failure compared with both Day 5 (OR: 2.22, 95% CI: 1.32-3.71) and Day 6 (OR: 1.93, 95% CI: 1.21-3.09) blastocysts. Moreover, the incidence of successful implantation significantly increased over time during the study period (OR: 1.11, 95% CI: 1.03-1.20). Qualitative data are presented as % (n/N). P < 0.017 was considered statistically significant according to Bonferroni adjustment for multiple comparisons.
Neonatal outcomes
In the second part of the study, a total of 1518 live born infants derived from 2832 included frozen-thawed blastocyst transfer cycles were analyzed, which consisted of 585, 869 and 64 newborns in Day-5, Day-6 and Day-7 vitrified embryo transfer groups, respectively (Fig. 1) . Neonatal outcomes of these live born infants and results of the posthoc power analysis are shown in Table V . Types of congenital malformations among live born infants are shown in Table VI . The rates of low birth weight, congenital malformations and early neonatal death were not statistically significant. Multiple birth was the only statistically significant risk factor for congenital malformations in the regression analysis. Multiple birth cycles were 5.70 times more likely to result in babies with congenital malformations as compared to singleton birth cycles (OR: 5.70, 95% CI: 1.42-22.92; P = 0.014). Multiple birth (x 1 ) was included in the logistic regression equation as: logit P = −5.685 + 1.740x 1 (P = 0.011, with the −2 log likelihood = 99.572, and the Nagelkerke R 2 = 0.064).
Discussion
The results of this retrospective cohort study suggest that Day-7 vitrified embryo transfers, although less successful than Day-5 and Day-6 vitrified embryo transfers, could still result in clinically relevant rates of pregnancy and live birth. Furthermore, Day 7 blastocysts did not result more often in low birth weight, congenital malformations and early neonatal death than Day 5 and Day 6 blastocysts. This information Continued indicates that embryos that do not achieve blastulation until Day 6 could be cultured for one more day, especially for women with limited Day 5 or Day 6 blastocysts. We also found vitrification day of transferred embryos is an independent risk factor for implantation failure, which indicates fast-grow blastocysts should be considered as a priority for transfer if they are in similar morphological grade to growthretarded blastocysts.
Strengths and limitations
A main strength of our study is that it included more than 200 Day-7 vitrified embryo transfers, resulting in 64 live born infants, which is the largest number reported on this topic to-date, offering a scarce opportunity to compare the neonatal outcomes among Day-5, Day-6 and Day-7 vitrified embryo transfers. Previous studies were case reports or cohort studies with limited samples (Table I) , and few studies on the neonatal outcomes of Day 7 blastocysts were available. Note: OR, odds ratio; ET, embryo transfer. Adjusted ORs were adjusted for all those covariates with adjusted OR in the table using a binary logistic regression model through backward conditional method. The −2 log likelihood=1629.78, and the Nagelkerke R We used propensity score matching to control for potential confounders among Day-5, Day-6 and Day-7 vitrified embryo transfers, making outcomes under these matched groups conditionally independent of treatment assignment. This method is useful in observational studies where treatment allocation is non-random and can be viewed as an approach seeking to replicate random assignment in conventional randomized controlled trials (Whittaker et al., 2016) . In other words, it enabled our attempt at evaluation of developmental potential of Day 5, Day 6 and Day 7 embryos independent from the maternal and FET characteristics that varied considerably among the three transfer groups.
This was a single center retrospective study with non-negligible limitations. In our center, the top-quality (grade I and II) embryos were vitrified on Day 3, while the morphologically poorer (grades III and IV) Day 3 embryos were extendedly cultured. Consequently, the best quality embryos were not included in our analysis. This may have reduced the differences between comparison groups, as all embryos started off as relatively poor-mid quality embryos. Furthermore, blastocysts graded 3BC or better were vitrified on Day 5 or 6, while the poorer blastocysts (3CC) were qualified for vitrification on Day 7. This protocol may make the Day 7 blastocysts morphologically poorer than the Day 5 or 6 blastocysts and could have lowered the pregnancy rate of Day 7 group. Nevertheless, Day 7 blastocysts still resulted in acceptable rates of clinical pregnancy (32.5%) and live birth (25.2%).
Most of the neonatal data in our center were extracted from parental questionnaires, rather than from direct access to medical records, which may compromise the detection of minor problems and result in an underestimated birth defect rates, although birth weight was unlikely to have been affected by this limitation.
Neither assisted hatching nor PGD was performed in our center, which limited our further analysis on whether assisted hatching could improve the fertility outcomes of Day 7 blastocysts, and the comparison of genetic status of embryos achieving blastulation on different days.
Because of the still limited number of Day-7 vitrified embryo transfers, the current study was unable to compare the fertility outcomes between poor morphologic grade Day 5 blastocysts and good morphologic grade Day 7 blastocysts. Furthermore, our study may be underpowered to detect the difference in extremely low rates such as ectopic pregnancy, congenital malformations and early neonatal death, and was unable to perform CI calculation. Instead, results of post-hoc power analysis on neonatal outcomes are presented in Table V . However, these data should be interpreted with caution because power calculations are based on plugging in true values of study parameters, whereas the actual data collected in any study are merely estimates that may or may not reflect the true treatment effect. Particularly, in a study with a small sample size, estimates are more likely to be inaccurate, so a post-hoc power calculation based on these estimates also is more likely to be inaccurate (Wallace and Melia, 2008) . Well-designed and adequately powered randomized controlled trials are needed to position Day-7 blastocyst transfer and blastocyst transfer in general.
Comparisons of results between ours and previous studies Shoukir et al. (Shoukir et al., 1998) studied 16 autologous FET cycles using Day 7 and Day 8 embryos in the 1990s and reported the pregnancy rate was 6.2%. This rate was similar to that of 9.7% in the prospective study conducted by Utsunomiya et al. (Utsunomiya et al., 2004) in 31 autologous fresh Day-7 embryo transfer cycles in the early 2000s. In 2006, Richter et al. (Richter et al., 2006) reported their research on 48 FET cycles transferring Day 7 blastocysts, which included both autologous and donor oocyte cycles. They found the pregnancy rate was 14.6%. However, in most of the more recent studies, the pregnancy rates of Day-7 blastocysts transfer cycles elevated dramatically. In a report of 11 cases of FET (Hiraoka et al., 2008) , the pregnancy rate of Day 7 blastocysts reached 54.5%, which was similar to that of Day 5 or Day 6 blastocysts in the same center. Zhao et al. (2015) compared the outcomes between Day 7 blastocysts which were 4-cells on Day 3 (n = 8 FETs) and those which were more than 4-cells on Day 3 (n = 7 FETs). The pregnancy rates were 37.5 and 42.9%, respectively. Kovalevsky et al. (2013) studied 30 FET cycles transferring Day 7 blastocysts and reported a pregnancy rate of 36.7%, which is close to that in our study. The increase of pregnancy rate of Day 7 blastocysts may be partly due to the following reasons. Firstly, assisted hatching was applied in most of the recent studies, whereas this technique was not used in the early studies. Latest meta-analyses of FET cycles (Carney et al., 2012) or pooled fresh and FET cycles suggested that assisted hatching could increase pregnancy rate. Secondly, in the recent studies, vitrification had become the main cryopreservation protocol instead of slow freeze, which may also improve outcomes (Richter et al., 2016; Rienzi et al., 2017) . Besides, in line with previous studies (Wade et al., 2015) , our single center data also show a significant increase of pregnancy rate of blastocyst transfer over time during the past decade, even though all the studied blastocysts underwent vitrification and had not been assisted hatched, which suggests there might be other unelucidated contributing factors related to the evolution of IVF overtime such as embryo culture media (Mantikou et al., 2013) . Still, it's possible that the controversy among the above studies might be caused by small numbers of Day-7 embryo transfers studied. Anyhow, this indicates the clinical value of Day 7 blastocysts needs to be appropriately reevaluated with the evolution of IVF overtime.
Reported rates of ongoing pregnancy and/or live birth of Day 7 blastocysts ranging from 6.5 to 36.4% (Utsunomiya et al., 2004; Hiraoka et al., 2008; Kovalevsky et al., 2013; Richter et al., 2016; Su et al., 2016) . Again, our result was in close proximity to the rate of 26.7% in the study conducted by Kovalevsky et al. (2013) .
The overall rate of congenital malformations among all the included live born infants in our study was 0.66%. This rate was very close but slightly lower than that of 0.73% in our previous study conducted in a population mainly undergoing cleavage embryo transfers. Many studies suggested that the extended culture for blastulation could serve as a possible selection process for embryos of superior viability and less genetic abnormality (Shoukir et al., 1998) . Indeed, by using array comparative genomic hybridization to assess all 24 chromosomes of Day 3 blastomere and Day 5 trophectoderm, Adler et al. (2014) found the aneuploidy rates were significantly higher in Day 3 embryos than in Day 5 embryos. This might be one of those factors accounting for the slightly lowered congenital malformation rate in the current study. In accordance with our previous study and other studies (Mastroiacovo et al., 1999) , we also found multiple birth was a significant risk factor for congenital malformations. Wang et al. (2016) compared the neonatal outcomes between 406 and 258 neonates derived from Day 5 and Day 6 blastocysts, respectively. In line with our results, they also did not observe a significant difference in rates of low birth weight, birth defects and neonatal death between the two groups.
Possible mechanisms of the decreased implantation potential
Developmental stage and morphological grade are two important factors affecting the implantation potential of blastocysts (Barash et al., 2017) . Our results show Day 7 blastocysts were associated with a higher proportion of embryos with inferior morphological grades but higher developmental stages. To distinguish the effect of the above two factors from the vitrification day of embryos transferred, we further performed a regression analysis among all the single blastocyst transfer cycles derived from all the included cycles, the results of which demonstrate growth retardation of embryos is an independent risk factor for implantation failure. Results from studies on whether growth retardation in blastocysts is associated with an increased risk of genetic abnormality are controversial. Some studies reported Day 6 blastocysts have higher rates of chromosomal aneuploidy compared with Day 5 blastocysts (Taylor et al., 2014; Barash et al., 2017) , whereas some other studies suggested the euploidy rates between Day 5 and Day 6 blastocysts did not differ (Capalbo et al., 2014; Yang et al., 2016) , and few studies investigated the genetic status of Day 7 blastocysts (Su et al., 2016) . Nevertheless, Hashimoto et al. (2013) analyzed 259 embryos that developed to the blastocyst stage on Day 5 and 274 embryos that achieved blastulation on Day 6. They found the incidence of abnormal spindles in the growth-retarded embryos was significantly higher than in the normally developing embryos (47 vs 30%, P < 0.01). An increase in abnormal spindles in embryos may likely lead to a decrease in implantation potential due to a drop in overall cell numbers through mitotic arrest. Indeed, they found the implantation rates were significantly higher in Day 5 blastocysts compared with that in Day 6 blastocysts. Our results further collaborate this theory by demonstrating the significant decrease of implantation rates with the increase of the time needed for blastulation among Day 5, Day 6 and Day 7 blastocysts. Besides, our results show that transfer of two Day 5 blastocysts resulted in significantly higher multiple gestation rate vs. transfer of the same number of Day 6 or 7 blastocysts, which also suggests that Day 5 blastocysts are more likely to implant in general. On the other hand, our results show the miscarriage rates and neonatal adverse outcomes were not significantly different among the Day 5, Day 6 and Day 7 blastocysts, which might indicate the negative effect of potential defects underlying delayed blastulation is mostly realized during implantation, and affects less afterwards. If so, the transfer of Day 7 blastocysts instead of discarding them in situations where there are not enough Day 5 and Day 6 blastocysts could significantly increase the possibility of live birth without adding risks. Further studies investigating the underlying mechanisms of the delayed blastulation are warranted.
Conclusions
Transfer of embryos that reach the blastocyst stage on Day 7 results in lower but still acceptable live birth rates, and seems to be safe for the offspring. Extension of the culture time in embryos that do not reach blastocyst stage by Day 6 should be assessed in randomized clinical trials. Growth retardation of embryos is an independent risk factor for implantation failure. Fast-grow blastocysts should be prior considered for transfer if they are in similar morphological grade with growthretarded blastocysts.
